COMBINATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PROPHYLAXIS OF NON-HODGKIN'S LYMPHOMA (NHL)

摘要

The present invention relates to combinations for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL) of a) a 2,3-dihydroimidazo[1,2-c]quinazoline compound, namely 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide, and b) one or more further active agents selected from the group consisting of PI3Kδ-selective inhibitor GS-1101, BTK inhibitor ibrutinib, IKK inhibitor BAY Compound B and refametinib (BAY 86-9766 (RDEA-119)), wherein non-Hodgkin's lymphoma (NHL) is selected from 1st line, 2nd line, relapsed or refractory lymphoma, indolent or agressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); to a pharmaceutical composition for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL) comprising a combination of a) said compound and b) said one or more further active agents.